Person looking directly at camera

A DIFFERENT FORM OF OLANZAPINE IS HERE.* FOCUS ON THEIR

COMEBACK

Improvement in symptoms (PANSS) and personal and social functioning (PSP) at week 8 vs placebo.1,2†

EXPLORE TRIAL DESIGN

*WELTRUZA is the only FDA-approved subcutaneous formulation of olanzapine.1

†In an 8-week, randomized, double-blind, placebo-controlled study in adults with acute schizophrenia exacerbation (N=675), the primary endpoint (318 mg, 425 mg, and 531 mg) showed greater reductions in Positive and Negative Syndrome Scale (PANSS) total score (-21.91, -23.44, and -21.93, respectively) versus placebo (-12.17). At week 8, the secondary endpoint was Personal and Social Performance (PSP), where scores improved by 10.31, 8.83, and 10.59, respectively, for WELTRUZA doses versus 5.59 for placebo.1

People featured are not actual patients, caregivers, or doctors.

WELTRUZA™ is a [new] once-monthly subcutaneous long-acting injectable formulation of olanzapine.1

The first and only subcutaneous long-acting injectable (LAI) form of olanzapine1

Positive and Negative Syndrome Scale (PANSS)

PANSS DATA

Clinical Global Impression—Severity (CGI-S)

CGI-S DATA

Personal and Social Performance (PSP)

PSP DATA

Schizophrenia Quality of Life Scale (SQLS)

SQLS DATA

Over 90% of clinicians preferred an LAI with a single-injection initiation regimen over more complex regimens requiring oral therapy or multiple injections.3

Study design: A one-time prospective, cross-sectional, observational survey of 70 patients and 35 HCPs participating in the SOLARIS trial. The survey collected patient-reported outcomes data and assessed attitudes toward and experiences with LAI treatment attributes, delivery of care, and treatment satisfaction.

SEE DOSING CONVERSION
Actor portrayals of a patient, doctor, and caregiver

For patients who are looking for a long-acting treatment, consider once-monthly WELTRUZA

Consider starting or transitioning appropriate patients who may benefit from an LAI formulation or prefer a subcutaneous route of administration.4,5

When transitioning patients from oral olanzapine or intramuscular immediate‑release olanzapine, give WELTRUZA the consecutive day.1

IDENTIFY ideal candidateS for WELTRUZA

A NEW CONSIDERATION FOR SCHIZOPHRENIA TREATMENT

​

References: 1. WELTRUZA™ (olanzapine) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Alavi M, Ridout SJ, Lee C, Harris B, Ridout KK. Predictors of long-acting injectable antipsychotic medication use in patients with schizophrenia spectrum, bipolar, and other psychotic disorders in a US community-based, integrated health system. Schizophr Bull Open. 2024;5(1):sgae011. 3. Cutler AJ, Gonzalez A, Suett M, et al. Patient and healthcare professional attitudes and trial experiences with a subcutaneous long-acting injectable olanzapine (TV-44749) for the treatment of schizophrenia. Presented at: Schizophrenia International Research Society (SIRS) 2025 Annual Congress; March 29-April 2, 2025; Chicago, IL. 4. Zacker C, Puckett JT, Kamal-Bahl S. Real-world adherence and discontinuation of oral antipsychotics and associated factors in a national sample of US Medicare beneficiaries with schizophrenia. Clinicoecon Outcomes Res. 2024;16:567-579. 5. Brasso C, Beoni AM, Colli G, Mariani GN, Rocca P. Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study. Ther Adv Psychopharmacol. 2025;15:20451253251367591.

​

Are you a healthcare professional?

The information on WELTRUZAhcp.com is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?